Editas Medicine (EDIT) Price & Analysis

Compare

3,482 Followers

EDIT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.91 - $4.44

Previous CloseN/A

Volume963.61K

Average Volume (3M)2.77M

Market Cap

$217.65M

Enterprise Value-$93.49M

Total Cash (Recent Filing)$220.96M

Total Debt (Recent Filing)$31.13M

Price to Earnings (P/E)―

Beta2.40

Next Earnings

Nov 10, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding83,712,860

10 Day Avg. Volume2,107,012

30 Day Avg. Volume2,767,214

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.43

Enterprise Value/Revenue-2.61

Enterprise Value/Gross Profit-2.97

Enterprise Value/Ebitda0.38

Forecast

1Y Price Target

$3.16

Price Target Upside26.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Innovation And Preclinical SuccessEditas has shown highly promising preclinical data from their Sickle Cell Disease and liver programs, indicating potential for future clinical success.

Technology And EfficacyEditas's therapy has achieved an editing rate far exceeding the therapeutic threshold, viewed as a risk-mitigating feature before clinical development.

Bears Say

Financial PerformanceEditas reported a net loss of $0.92 per share, which was larger than the prior estimate of a net loss of $0.55 per share.

Legal And Patent IssuesThere is increasing uncertainty in the Cas9 patent interference case as the appellate court has instructed PTAB to reconsider its decision.

Editas Medicine News

Editas Medicine Unveils Promising Gene Editing Data

Editas Medicine ( ($EDIT) ) just unveiled an update. On June 12, 2025, Editas Medicine announced new in...

2M ago

EDIT

Promising Outlook for Editas Medicine: Strong Preclinical Data and Projected Financial Success

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Editas Medicine (EDIT – Research Report) today and...

2M ago

EDIT

Editas says levels of HBG1/2 promoter editing in hematopoietic stem cells

Editas Medicine (EDIT) shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic...

2M ago

EDIT

Editas Medicine Stockholders Approve Key Amendments

Editas Medicine ( ($EDIT) ) just unveiled an update. At the 2025 Annual Meeting of Stockholders held on...

2M ago

EDIT

Prime Medicine price target lowered to $12 from $16 at Chardan

Chardan analyst Geulah Livshits lowered the firm’s price target on Prime Medicine (PRME) to $12 from $16 and...

3M ago

EDIT

PRME

Cautious Outlook on Editas Medicine: Hold Rating Amidst Preclinical Progress and Financial Considerations

JonesTrading analyst Soumit Roy has maintained their neutral stance on EDIT stock, giving a Hold rating on May...

3M ago

EDIT

Promising Preclinical Data and Market Opportunities Drive Buy Rating for Editas Medicine

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Editas Medicine (EDIT – Research Report) today and...

3M ago

EDIT

Editas Medicine Reports Q1 2025 Progress and Financials

Editas Medicine Inc. ( ($EDIT) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

EDIT

Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs

Editas Medicine (EDIT) shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic...

3M ago

EDIT

Editas Medicine Unveils Promising Gene Editing Data

Editas Medicine ( ($EDIT) ) has issued an announcement. On May 14, 2025, Editas Medicine announced new in...

3M ago

EDIT

Editas Medicine Unveils In Vivo Gene Editing Data

Editas Medicine ( ($EDIT) ) has shared an announcement. On May 13, 2025, Editas Medicine announced in vivo...

3M ago

EDIT

Editas Medicine reports new in vivo proof of concept data for liver target

Editas Medicine (EDIT) shared in vivo proof of concept data supporting the development of a potentially first-in-class treatment...

3M ago

EDIT

Editas Medicine price target lowered to $4 from $8 at Baird

Baird lowered the firm’s price target on Editas Medicine (EDIT) to $4 from $8 and keeps an Outperform...

3M ago

EDIT

Editas Medicine: Hold Rating Amid Legal Uncertainty and Financial Concerns

In a report released today, Yanan Zhu from Wells Fargo maintained a Hold rating on Editas Medicine (EDIT...

3M ago

EDIT

EDIT FAQ

What was Editas Medicine Inc’s price range in the past 12 months?

Editas Medicine Inc lowest stock price was $0.91 and its highest was $4.44 in the past 12 months.

What is Editas Medicine Inc’s market cap?

Editas Medicine Inc’s market cap is $217.65M.

When is Editas Medicine Inc’s upcoming earnings report date?

Editas Medicine Inc’s upcoming earnings report date is Nov 10, 2025 which is in 94 days.

How were Editas Medicine Inc’s earnings last quarter?

Currently, no data Available

Is Editas Medicine Inc overvalued?

According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Editas Medicine Inc pay dividends?

Editas Medicine Inc does not currently pay dividends.

What is Editas Medicine Inc’s EPS estimate?

Editas Medicine Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Editas Medicine Inc have?

Editas Medicine Inc has 83,712,860 shares outstanding.

What happened to Editas Medicine Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Editas Medicine Inc?

Currently, no hedge funds are holding shares in EDIT

Editas Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

-140.82%

Trailing 12-Months

Asset Growth

-40.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Editas Medicine Inc

Editas Medicine (EDIT) is a leading biotechnology company focused on developing transformative genomic medicines. The company specializes in the field of gene editing, primarily utilizing CRISPR technology, to develop treatments for a wide range of serious diseases. By applying its proprietary gene-editing platform, Editas aims to create innovative therapies that can potentially correct genetic defects at their source, offering new possibilities for patients with unmet medical needs.

Editas Medicine (EDIT) Earnings & Revenues

Historic Earnings Reports

EDIT Stock 12 Month Forecast

Average Price Target

$3.16

▲(26.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.25,2.3846153846153846,2.519230769230769,2.6538461538461537,2.7884615384615383,2.923076923076923,3.0576923076923075,3.1923076923076925,3.3269230769230766,3.4615384615384617,3.596153846153846,3.730769230769231,3.8653846153846154,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.25,2.32,2.39,2.46,2.5300000000000002,2.6,2.67,2.74,2.81,2.88,2.95,3.02,3.09,{"y":3.16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.25,2.1538461538461537,2.0576923076923075,1.9615384615384615,1.8653846153846154,1.7692307692307692,1.673076923076923,1.5769230769230769,1.4807692307692308,1.3846153846153846,1.2884615384615383,1.1923076923076923,1.096153846153846,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.47,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.14,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >